BeiGene (Hong Kong) and Guangzhou GET Technology Development are setting up a joint venture (j-v), BeiGene Biologics, to build a commercial-scale biologics manufacturing facility in Guangzhou ...

BeiGene’s Guangzhou manufacturing facility has been designed to operate in compliance with current Good Manufacturing Practice (cGMP) standards adopted by the U.S. Food & Drug Administration ...

BeiGene Ltd, a global oncology company, announced on Monday the completion of its antibody-drug conjugate production facility in Guangzhou, capital of Guangdong province, demonstrating its ...

* Beigene - for additional funding, manufacturing factory subsidiary of JV company expected to secure commercial loans of RMB 1 billion or $150 million * Beigene Ltd - cash contributions to ...

today announced the official launch of the BeiGene Bioisland Innovation Center (BIC) in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated ...

The China National Medical Products Administration (NMPA) gave BeiGene the green light to start commercial manufacturing of the monoclonal antibody tislelizumab from the plant in Guangzhou.

State-of-the-Art Facility to Break Ground in 2017 Expected Direct Investments Total RMB2.2 Billion ($330 million) Funding Includes Support for Clinical Development in China BEIJING and GUANGZHOU, ...

Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment ...